跳至主要内容
临床试验/NCT03251469
NCT03251469Unknown2 期

Single Dose of Tranexamic Acid at the Time of Surgery and Blood Loss, in Elderly Patients Undergoing Hip Fracture Surgery

National and Kapodistrian University of Athens1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
200
试验地点
1
主要终点
total blood loss from surgery to day

研究概览

简要总结

The aim of this study is to investigate the hypothesis that single dose of tranexamic acid (TXA) preoperatively will lower blood loss and transfusion rate in elderly patients with hip fractures (intertrochanteric or Subcapital), that will be treated with intramedullary nailing and cemented hemiarthroplasty respectively. After application of inclusion and exclusion criteria, patients will be randomized in two groups. Group 1 will include patients that receive preoperatively single dose of TXA (15mg/kg) and Group 2 will include patients that receive normal saline (control group).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
75 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Consecutive elderly patients (age >75 yo) undergoing hip fracture surgery for a stable or unstable intertrochanteric hip fracture with the insertion of a short intramedullary nail (IMN) as well as patients treated surgically with cemented hemiarthroplasty for acute femoral neck (subcapital) hip fracture.

排除标准

  • Any contraindication for tranexamic acid
  • Multiple fractures
  • Requirement for anticoagulant therapy that could not be stopped.
  • Ongoing thromboembolic event
  • reduced kidney function
  • malignancy,
  • pathological fracture
  • previous operation on the affected hip
  • Active coronary artery disease (event in the past 12 months).

研究组 & 干预措施

Group 1

Active Comparator

intravenous tranexamic acid, 15mg/kg, preoperatively, single dose

干预措施: Tranexamic Acid 15mg/kg , iv, Single Dose (Drug)

Group 2

Placebo Comparator

Intravenous normal saline, 100mg, preoperatively, single dose

干预措施: Normal Saline, 100mg, iv, Singe dose (Drug)

结局指标

主要结局

total blood loss from surgery to day

时间窗: 5 days

number of transfusions of allogeneic RBC from surgery up to day 4

时间窗: 5 days

次要结局

  • incidence of vascular events(3 months)
  • Incidence of deaths(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Vasileios S. Nikolaou

Assistant Professor of Orthopaedics

National and Kapodistrian University of Athens

研究点 (1)

Loading locations...

相似试验